Feasibility of Implementation of the Early Tumor Shrinkage As a Potential Predictive Marker to Daily Clinical Practice in Patients with RAS Wild Type Metastatic Colorectal Cancer, Treated with Cetuximab – a Non-Interventional Observational Study